Haematologica, Vol 93, Issue 1, 6-9 doi:10.3324/haematol.12324
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tefferi, A.
Right arrow Articles by Pardanani, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tefferi, A.
Right arrow Articles by Pardanani, A.
Related Collections
Right arrowRelated Article

Editorials and Perspectives

How we diagnose and treat WHO-defined systemic mastocytosis in adults

Ayalew Tefferi, Srdan Verstovsek, Animesh Pardanani

Division of Hematology, Mayo Clinic, Rochester, MN, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA. E-mail: tefferi.ayalew{at}mayo.edu

Current classification and diagnosis of systemic mastocytosis, and its distinction from other myeloid malignancies associated with bone marrow mastocytosis, remain challenging for both clinicians and hematopathologists. In its upcoming revision, due out in 2008, the World Health Organization (WHO) classification system for myeloid malignancies considers mast cell disease as a myeloproliferative neoplasm and systemic mastocytosis as a subcategory of mast cell disease with bone marrow involvement.1 At the same time, the WHO document distinguishes the usually KIT-mutated systemic mastocytosis from myeloid neoplasms associated with bone marrow mastocytosis and PDGFR mutations (e.g. FIP1L1-PDGFRA, PRKG2-PDGFRB).2–6 The latter are often associated with eosinophilia or basophilia and sensitive to treatment with imatinib. WHO-defined systemic mastocytosis is sometimes associated with a clonally-related second myeloid neoplasm,7–11 which is not surprising considering its origin as a stem cell disease with multilineage clonal involvement.12–16 Conversely, an otherwise well-defined myeloid malignancy, such as myelodysplastic syndrome or a non-mast cell disease myeloproliferative neoplasm, might harbor neoplastic mast cells.17

Our approach to diagnosis in systemic mastocytosis starts with bone marrow examination with tryptase staining and mast cell CD25 immunophenotyping. The former enhances morphologic and the latter immunophenotypic distinction between normal (round and CD25-negative) and abnormal (spindle-shaped and CD25-positive) mast cells.18,19 Bone marrow examination also allows detection of a second hematologic neoplasm, if present.7,9 In addition, in the presence of blood eosinophilia, we screen for FIP1L1-PDGFRA, using either FISH or RT-PCR.20 By contrast, we rely on conventional cytogenetics to identify cases of bone marrowmastocytosis associated with a PDGFRB rearrangement (i.e. chromosomal translocations involving 5q31-32).6 In general, we consider mutation screening for KITD816V and measurement of serum tryptase or urinary histamine metabolites as being complementary for the diagnosis of mast cell disease.21–23 It is to be noted that the likelihood of detecting a KIT mutation is significantly higher with the use of both highly sensitive PCR-based assay and mast cell-enriched test samples.24,25

After establishing the presence of abnormal bone marrow mast cells, we strictly follow the revised WHO criteria in assigning the specific diagnosis of myeloid neoplasm associated with PDGFR rearrangement, in the presence of either a PDGFRA or PDGFRB mutation.1 In all other instances, we use the term systemic mastocytosis, provided bone marrow mastocytosis is the prominent feature in terms of both bone marrow histology and clinical presentation. Drug therapy has not been shown to favorably affect survival in systemic mastocytosis and the experience with allogeneic stem cell transplantation has been too limited to allow discussion.26 Therefore, current therapy in WHO-defined systemic mastocytosis is palliative and directed at mast cell degranulation symptoms (e.g. pruritus, urticaria, angioedema, flushing, nausea, vomiting, abdominal pain, diarrhea, episodic anaphylactoid attacks), skin disease such as urticaria pigmentosa, and/or organ dysfunction from mast cell tissue infiltration. In general, antihistamines and cromolyn sodium are equally effective (or ineffective) in controlling mast cell degranulation symptoms.27 Urticaria pigmentosa and pruritus respond modestly to topical corticosteroids or ultraviolet A phototherapy with (PUVA) or without (UVA1) psoralen.28–31 We also consider interferon-{alpha} therapy for mast cell degranulation symptoms and urticaria pigmentosa that are refractory to usual therapy.32

The presence of organ dysfunction (e.g. symptomatic hepatosplenomegaly, clinically-significant liver function test abnormalities, ascites, cytopenias, osteoporosis or osteolysis, diarrhea associated with weight loss) distinguishes indolent from aggressive systemic mastocytosis. In general, we try to avoid the use of cytoreductive agents in patients with indolent systemic mastocytosis, where survival is usually long and disease course non-progressive.33–35 By contrast, cytoreductive therapy is usually employed in aggressive systemic mastocytosis with the intention to decrease mast cell burden. Here, interferon-{alpha} and cladribine are the first-line drugs of choice and we expect response rates of >50% with each drug.36,37 Treatment with either interferon-{alpha} or cladribine has the potential to benefit all aspects of disease, including mast cell degranulation symptoms, urticaria pigmentosa, symptomatic organomegaly and ascites. In the presence of osteoporosis or lytic bone lesions, we recommend, in addition, bisphosphonate therapy (e.g. pamidronate 90 mg IV monthly).38,39

Unfortunately, current therapy for patients with systemic mastocytosis who fail treatment with either interferon-{alpha} or cladribine is inadequate and we highly recommend that such patients participate in experimental treatment protocols. In this setting, in vitro activity against KITD816V or KITD814Y has been demonstrated for several kinase inhibitors such as PKC412,40,41 dasatinib,42,43 EXEL-0862,44 SU5416,45 SU6577,46 MLN51847 and other drugs including 17-AAG (binds heat-shock protein 90),48 IMD-0354 (an NF-{kappa}B inhibitor)49 and rapamycin (an mTOR inhibitor).50 Of relevance to the latter agent, PI3K/Akt signaling has been implicated in mutant KIT-associated cell transformation and rapamycin has been shown to induce apoptosis in D816V-positive mast cell lines, inhibit survival of D816V-positive but not wild-type primary cells from patients with systemic mastocytosis, and suppress ligand-independent growth of KITD814V-expressing cell lines.50–52 Phase II clinical trials in systemic mastocytosis involving several of the aforementioned drugs (e.g. dasatinib, PKC412, and RAD001, a rapamycin analog) are currently ongoing.53

References

  1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007;[Epub ahead of print].
  2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-4.[Abstract/Free Full Text]
  3. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-45.[Abstract/Free Full Text]
  4. Dalal BI, Horsman DE, Bruyere H, Forrest DL. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation. Am J Hematol 2007;82:77-9.[CrossRef][Web of Science][Medline]
  5. Lahortiga I, Akin C, Cools J, et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008;93:49-56.[Abstract/Free Full Text]
  6. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene. Haematologica 2007;92:163-9.[Abstract/Free Full Text]
  7. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988;62:965-72.[CrossRef][Medline]
  8. Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007;31:261-5.[CrossRef][Web of Science][Medline]
  9. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004;57:604-8.[Abstract/Free Full Text]
  10. Sperr WR, Drach J, Hauswirth AW, Ackermann J, Mitterbauer M, Mitterbauer G, et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005;11:6787-92.[Abstract/Free Full Text]
  11. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000;53:188-193.[Abstract/Free Full Text]
  12. Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG, et al. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 2004;6:335-42.[Abstract/Free Full Text]
  13. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003;27:883-5.[CrossRef][Web of Science][Medline]
  14. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004;89:871-3.[Abstract/Free Full Text]
  15. Afonja O, Amorosi E, Ashman L, Takeshita K. Multilineage involvement and erythropoietin-"independent" erythroid progenitor cells in a patient with systemic mastocytosis. Ann Hematol 1998;77:183-6.[CrossRef][Web of Science][Medline]
  16. Kocabas CN, Yavuz AS, Lipsky PE, Metcalfe DD, Akin C. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. J Allergy Clin Immunol 2005;115:1155-61.[CrossRef][Web of Science][Medline]
  17. Dunphy CH. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. Arch Pathol Lab Med 2005;129:219-22.[Web of Science][Medline]
  18. Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777-83.[CrossRef][Web of Science][Medline]
  19. Li WV, Kapadia SB, Sonmez-Alpan E, Swerdlow SH. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod Pathol 1996;9:982-8.[Web of Science][Medline]
  20. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 2003;102:3093-6.[Abstract/Free Full Text]
  21. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-72.[Abstract/Free Full Text]
  22. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316:1622-6.[Abstract]
  23. Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983;309:1603-5.[Abstract]
  24. Zhao W, Bueso-Ramos CE, Verstovsek S, Barkoh BA, Khitamy AA, Jones D. Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease. Leukemia 2007;21:1574-6.[CrossRef][Web of Science][Medline]
  25. Corless CL, Harrell P, Lacouture M, Bainbridge T, Le C, Gatter K, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8:604-12.[Abstract/Free Full Text]
  26. Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006;37:353-8.[CrossRef][Web of Science][Medline]
  27. Frieri M, Alling DW, Metcalfe DD. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med 1985;78:9-14.[Web of Science][Medline]
  28. Barton J, Lavker RM, Schechter NM, Lazarus GS. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol 1985;121:1516-23.[Abstract/Free Full Text]
  29. Lavker RM, Schechter NM, Guzzo C, Lazarus GS. Aggressive topical corticosteroid therapy: a novel approach to mast-cell-dependent cutaneous disorders. Dermatologica 1987;175:213-6.[Web of Science][Medline]
  30. Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997;195:35-9.[Web of Science][Medline]
  31. Gobello T, Mazzanti C, Sordi D, Annessi G, Abeni D, Chinni LM, et al. Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol 2003;49:679-84.[CrossRef][Web of Science][Medline]
  32. Simon J, Lortholary O, Caillat-Vigneron N, Raphaël M, Martin A, Brière J, et al. Interest of interferon {alpha} in systemic mastocytosis. The French experience and review of the literature. Group AFIRMM (Association française pour les initiatives de recherche sur le mastocyte et les mastocytoses). Pathol Biol (Paris) 2004;52:294-9.[Medline]
  33. Kors JW, Van Doormaal JJ, Breukelman H, Van Voorst Vader PC, De Monchy JG. Long-term follow-up of indolent mastocytosis in adults. J Intern Med 1996;239:157-64.[CrossRef][Web of Science][Medline]
  34. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991;96:5S-13S.[CrossRef][Medline]
  35. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991;91:612-24.[CrossRef][Web of Science][Medline]
  36. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, et al. Response to therapy with interferon {alpha}-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004;28:249-57.[CrossRef][Web of Science][Medline]
  37. Kluin-Nelemans HC, Oldhoff JM, van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, et al. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270-6.[Abstract/Free Full Text]
  38. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997;36:393-6.[Abstract/Free Full Text]
  39. Laroche M, Bret J, Brouchet A, Mazieres B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 2007;26:242-3.[CrossRef][Web of Science][Medline]
  40. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006;107:752-9.[Abstract/Free Full Text]
  41. Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005;106:2865-70.[Abstract/Free Full Text]
  42. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108:286-91.[Abstract/Free Full Text]
  43. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.[Abstract/Free Full Text]
  44. Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007;109:315-22.[Abstract/Free Full Text]
  45. Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 2007;26:3904-8.[CrossRef][Web of Science][Medline]
  46. Ma Y, Carter E, Wang X, Shu C, McMahon G, Longley BJ. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. J Invest Dermatol 2000;114:392-4.[CrossRef][Web of Science][Medline]
  47. Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL, et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 2004;104:3754-7.[Abstract/Free Full Text]
  48. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004;103:1078-84.[Abstract/Free Full Text]
  49. Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005;105:2324-31.[Abstract/Free Full Text]
  50. Gabillot-Carre M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 2006;108:1065-72.[Abstract/Free Full Text]
  51. Munugalavadla V, Sims EC, Borneo J, Chan RJ, Kapur R. Genetic and pharmacologic evidence implicating the p85{{alpha}}, but not p85{β}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood 2007;110:1612-20.[Abstract/Free Full Text]
  52. Shivakrupa R, Bernstein A, Watring N, Linnekin D. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 2003;63:4412-9.[Abstract/Free Full Text]
  53. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429-39.[CrossRef][Medline]

Related Article

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
Idoya Lahortiga, Cem Akin, Jan Cools, Todd M. Wilson, Nicole Mentens, Diane C. Arthur, Irina Maric, Pierre Noel, Can Kocabas, Peter Marynen, Lawrence S. Lessin, Iwona Wlodarska, Jamie Robyn, Dean D. Metcalfe
Haematologica 2008 93: 49-56. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
A. M. Vannucchi, P. Guglielmelli, and A. Tefferi
Advances in Understanding and Management of Myeloproliferative Neoplasms
CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tefferi, A.
Right arrow Articles by Pardanani, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tefferi, A.
Right arrow Articles by Pardanani, A.
Related Collections
Right arrowRelated Article